Rami Hannoush
Private Equity Investor at Versant Venture Management LLC
Profile
Rami Hannoush is the founder of EpiBiologics, Inc. He is currently a Venture Partner at Versant Venture Management LLC.
Previously, he worked as a General Partner at Mubadala Capital and as a Board Member at Juvena Therapeutics, Inc. Hannoush holds a doctorate degree from McGill University and a graduate degree from Harvard Medical School.
Rami Hannoush active positions
| Companies | Position | Start |
|---|---|---|
Versant Venture Management LLC
 Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Private Equity Investor | 2023-01-31 |
Former positions of Rami Hannoush
| Companies | Position | End |
|---|---|---|
EpiBiologics, Inc.
 EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Chief Executive Officer | 2023-07-19 |
Juvena Therapeutics, Inc.
 Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Director/Board Member | 2023-02-28 |
Mubadala Capital
 Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Private Equity Investor | 2023-01-31 |
Training of Rami Hannoush
| McGill University | Doctorate Degree |
| Harvard Medical School | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 4 |
|---|---|
Versant Venture Management LLC
Versant Venture Management LLC Investment ManagersFinance Versant Venture Management LLC (Versant Ventures) is an independent venture capital firm founded in 1999 by Brian Atwood, Samuel Colella, Bill Link and Ross Jaffe. The firm is headquartered in San Francisco with additional offices in Basel and Vancouver. | Finance |
Mubadala Capital
Mubadala Capital Investment ManagersFinance Mubadala Capital (Mubadala Capital) is a private equity subsidiary of Mubadala Investment Co. PJSC founded in 2011. The firm is headquartered in Abu Dhabi, United Arab Emirates with offices in London, New York, Rio De Janeiro, and San Francisco. | Finance |
Juvena Therapeutics, Inc.
Juvena Therapeutics, Inc. BiotechnologyHealth Technology Juvena Therapeutics, Inc. develops protein-based therapeutics that promotes tissue regeneration in the elderly. The company was founded by Hanadie Yousef and Jeremy O'connell in 2017 and is headquartered in Palo Alto, CA. | Health Technology |
EpiBiologics, Inc.
EpiBiologics, Inc. Miscellaneous Commercial ServicesCommercial Services EpiBiologics, Inc. is an American biotech company that is developing a protein degradation platform to target membrane and extracellular proteins. The company is headquartered in an undisclosed location and is backed by leading healthcare investors. The company is based in San Francisco, CA. EpiBiologics' proprietary epitac platform is an antibody-based system that can precisely degrade disease-driving proteins in a tissue-specific manner. EpiBiologics aims to develop first-in-class and targeted therapies for cancer, immunology, and neurological diseases. The company was founded in 2022 by Dr. Jim Wells of the University of California, San Francisco (UCSF). Ann Lee-Karlon has been the CEO of the company since 2023. | Commercial Services |
- Stock Market
- Insiders
- Rami Hannoush
